BridgeBio Pharma, Inc.

NasdaqGS:BBIO Stock Report

Market Cap: US$5.4b

BridgeBio Pharma Future Growth

Future criteria checks 3/6

BridgeBio Pharma is forecast to grow earnings and revenue by 26.1% and 43.6% per annum respectively. EPS is expected to grow by 26.5% per annum. Return on equity is forecast to be 27.7% in 3 years.

Key information

26.1%

Earnings growth rate

26.5%

EPS growth rate

Biotechs earnings growth27.6%
Revenue growth rate43.6%
Future return on equity27.7%
Analyst coverage

Good

Last updated20 Dec 2024

Recent future growth updates

Recent updates

BridgeBio: Next Chapter Begins After Attruby Approval

Nov 24

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be

Nov 19
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Analysts Are More Bearish Than They Used To Be

Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Sep 24
Revenues Not Telling The Story For BridgeBio Pharma, Inc. (NASDAQ:BBIO)

BridgeBio: With HELIOS-B Overhang Removed, Focus To Turn To Approval And Launch Of Acoramidis

Aug 31

BridgeBio Pharma's Acoramidis Leads Promising Pipeline With FDA Approval On Horizon

Aug 17

BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

Jun 10
BridgeBio Pharma, Inc.'s (NASDAQ:BBIO) Popularity With Investors Is Under Threat From Overpricing

BridgeBio Pharma: Upping An Existing Position (Rating Upgrade)

Jun 03

BridgeBio Pharma: FDA Submission Acromidis And Top Line Results On Deck

Jan 11

Earnings and Revenue Growth Forecasts

NasdaqGS:BBIO - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026420-602-500-52711
12/31/2025181-713-649-53117
12/31/2024313-475-355-40417
9/30/2024218-439-456-450N/A
6/30/2024219-454-420-415N/A
3/31/2024219-538-606-603N/A
12/31/20239-643-529-528N/A
9/30/20239-613-498-496N/A
6/30/20236-573-488-486N/A
3/31/202378-425-409-403N/A
12/31/202278-481-426-419N/A
9/30/202289-491-468-460N/A
6/30/202291-509-495-447N/A
3/31/202271-596-555-508N/A
12/31/202170-563-546-498N/A
9/30/202157-535-508-460N/A
6/30/202163-495-477-470N/A
3/31/20219-520-472-467N/A
12/31/20208-449-407-400N/A
9/30/202022-402-387-380N/A
6/30/202041-346-305-298N/A
3/31/202041-291-286-278N/A
12/31/201941-261-256-254N/A
9/30/201927-226-228-224N/A
6/30/2019N/A-197-216-212N/A
3/31/2019N/A-155-183-178N/A
12/31/2018N/A-131-155-137N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BBIO is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: BBIO is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: BBIO is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: BBIO's revenue (43.6% per year) is forecast to grow faster than the US market (9.1% per year).

High Growth Revenue: BBIO's revenue (43.6% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: BBIO's Return on Equity is forecast to be high in 3 years time (27.7%)

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 21:51
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

BridgeBio Pharma, Inc. is covered by 24 analysts. 17 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
George FarmerBMO Capital Markets Equity Research
Konstantinos BiliourisBMO Capital Markets Equity Research
Jason ZemanskyBofA Global Research